Promise & Pitfalls of Tumor Target Quantification in Antibody-Drug Conjugate & Immune Cell Engager Drug Development

• Target expression in indication selection and as potential predictive biomarkers
• Digital pathology approaches and technical challenges
• Optimizing program investment and deciding what data will be enough

Speakers:

Lauri Diehl

Executive Director, Research Pathology

Gilead Sciences